SEARCH:   Advanced

Blood, 30 April 2009, Vol. 113, No. 18, pp. 4144-4152. Prepublished online as a Blood First Edition Paper on January 23, 2009; DOI 10.1182/blood-2008-10-184200. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-10-184200v1 113/18/4144    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tam, C. S. Articles by Khouri, I. F. Search for Related Content PubMed PubMed Citation Articles by Tam, C. S. Articles by Khouri, I. F. Related Collections Transplantation Free Research Articles Lymphoid Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Constantine S. Tam1,2, Roland Bassett3, Celina Ledesma2, Martin Korbling2, Amin Alousi2, Chitra Hosing2, Partow Kebraei2, Robyn Harrell3, Gabriela Rondon2, Sergio A. Giralt2, Paolo Anderlini2, Uday Popat2, Barbara Pro4, Barry Samuels5, Frederick Hagemeister4, L. Jeffrey Medeiros6, Richard E. Champlin2, and Issa F. Khouri2 1 Department of Hematology, St Vincent's Hospital, Melbourne, Australia; and Departments of 2 Stem Cell Transplantation and Cellular Therapy, 3 Biostatistics, 4 Lymphoma and Myeloma, 5 Medical Imaging, and 6 Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston In this study, we analyzed the long-term outcome of a risk-adapted transplantation strategy for mantle cell lymphoma in 121 patients enrolled in sequential transplantation protocols. Notable developments over the 17-year study period were the addition of rituximab to chemotherapy and preparative regimens and the advent of nonmyeloablative allogeneic stem cell transplantation (NST). In the autologous transplantation group (n = 86), rituximab resulted in a marked improvement in progression-free survival for patients who received a transplant in their first remission (where a plateau emerged at 3-8 years) but did not change the outcomes for patients who received a transplant beyond their first remission. In the NST group, composed entirely of patients who received a transplant beyond their first remission, durable remissions also emerged in progression-free survival at 5 to 9 years. The major determinants of disease control after NST were the use of a peripheral blood stem cell graft and donor chimerism of at least 95%, whereas the major determinant of death was immunosuppression for chronic graft-versus-host disease. Our results show that long-term disease-free survival in mantle cell lymphoma is possible after rituximab-containing autologous transplantation for patients in first remission and after NST for patients with relapsed or refractory disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. J. Moskowitz and C. H. Moskowitz Controversies in the Treatment of Lymphoma with Autologous Transplantation Oncologist, September 1, 2009; 14(9): 921 - 929. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020